Table 2.

Univariate survival analysis of clinical parameters and the risk score with PFS and OS in the Tianjin cohort.

Clinical parameters		n	PFS	p-value	OS	p-value
			Hazard ratio		Hazard ratio
			(95% CI)		(95% CI)
Age (years)
	<65	132	1.299	0.227	1.336	0.282
	≥65	48	(0.825~2.046)		(0.760~2.348)
Gender
	Males	79	0.846	0.403	0.732	0.212
	Females	101	(0.568~1.261)		(0.443~1.208)
Clinical stage
	I+II	122	3.304	<0.0001***	4.834	<0.0001***
	III	58	(2.067~5.281)		(2.710~8.623)
Tumor
	T1	95	2.300	<0.0001***	2.408	0.0005***
	T2+T3+T4	85	(1.536~3.444)		(1.460~3.971)
Lymph node
	N0	113	2.954	<0.0001***	4.387	<0.0001***
	N1+N2	67	(1.913~4.562)		(2.557~7.527)
Smoke
	No smoking	114	1.091	0.675	1.364	0.221
	Smoking	66	(0.721~1.652)		(0.810~2.298)
PTTG1
	Low	75	3.936	<0.0001***	3.798	<0.0001***
	High	105	(2.654~5.837)		(2.316~6.228)
SLC2A1
	Low	81	4.105	<0.0001***	8.024	<0.0001***
	High	99	(2.758~6.110)		(4.890~13.17)
FAM83A
	Low	128	2.943	<0.0001***	3.909	<0.0001***
	High	52	(1.809~4.785)		(2.175~7.025)
Risk score
	Low	93	5.519	<0.0001***	10.96	<0.0001***
	High	87	(3.638~8.372)		(6.597~18.20)

***p < 0.001.

Bold values indicate statistical significance p < 0.05.